The Biospecimen, Pathology and Genomics Core for the Yale Lung Cancer SPORE will serve as the nexus for all human biospecimen acquisition, processing and analysis for all SPORE-sponsored research as well as provide support for all non-human model system specimen molecular analytics not currently offered through Yale shared facilities. Tissue biopsy procurement will be coordinated with all interventionalists and surgeons as this occurs at the bedside or in the operating room with research tissues derived from extra passes of the biopsy needle after the diagnostic specimen has been collected or collection at the surgical pathology bench. The Biospecimen, Pathology and Genomics Core will work closely with Yale Pathology Tissue Services, the research tissue procurement service supported within the Department of Pathology (also directed by David Rimm) to obtain fresh resection specimens. Specifically the Biospecimen, Pathology and Genomics Core will: 1) coordinate the acquisition, processing, aliquoting, storage and distribution for all whole blood samples and their derivatives (e.g., plasma, serum, buffy coat) required for the described research in Projects 1-4 as well as the Developmental and Career Development Award Programs? approved projects; 2) coordinate the acquisition, handling, storage and distribution for all lung cancer tissue sample collection required for Projects 1-4, Developmental and Career Development Awards; 3) generate conditionally reprogrammed primary lung cancer cell lines from fresh tissue samples for use in Projects 1-3; and 4) conduct molecular pathology experiments including partial support of whole exome sequencing, RNA-Seq and Copy Number Variation analysis (Projects 2 and 3); quantitative microRNA in situ hybridization (Projects 1 and 2) and other molecular pathology support as needed during the term of the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196530-04
Application #
9529580
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Wilson, Frederick H; Politi, Katerina (2018) ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discov 8:676-678
Wang, Guangchuan; Chow, Ryan D; Ye, Lupeng et al. (2018) Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Sci Adv 4:eaao5508
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Anastasiadou, Eleni; Jacob, Leni S; Slack, Frank J (2018) Non-coding RNA networks in cancer. Nat Rev Cancer 18:5-18
Bisserier, Malik; Wajapeyee, Narendra (2018) Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas. Blood 131:2125-2137
Chow, Ryan D; Chen, Sidi (2018) Cancer CRISPR Screens In Vivo. Trends Cancer 4:349-358
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Goldberg, Sarah B; Narayan, Azeet; Kole, Adam J et al. (2018) Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res 24:1872-1880
Gilles, Maud-Emmanuelle; Slack, Frank J (2018) Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opin Ther Targets 22:929-939
Nagarajan, Maxwell B; Tentori, Augusto M; Zhang, Wen Cai et al. (2018) Nonfouling, Encoded Hydrogel Microparticles for Multiplex MicroRNA Profiling Directly from Formalin-Fixed, Paraffin-Embedded Tissue. Anal Chem 90:10279-10285

Showing the most recent 10 out of 74 publications